Kidney diseases are major global health problems, with high prevalence and mortality. However, current treatment strategies for kidney diseases fail to achieve satisfactory efficacy. Mesenchymal stem cell (MSC)-based therapy has been a promising strategy for treating kidney diseases. Preclinical studies have proven their safety and effectiveness in treating acute kidney injury (AKI) and chronic kidney disease (CKD), but the outcomes of clinical trials have shown very limited clinical efficacy. A variety of innovative approaches have been proposed to enhance the therapeutic potential of MSCs, and hydrogels are attractive candidates. Hydrogels are three-dimensional (3D) networks formed by hydrophilic polymers of natural or synthetic origin with diverse physical and chemical properties. They have been widely applied in the field of drug delivery and regenerative medicine, including MSC-based therapy. Many studies have proven that hydrogels can improve the therapeutic efficacy of MSCs for kidney diseases, but there are still challenges limiting the widespread application of this method. In this review, we introduce the application of MSCs in kidney diseases and the factors that influence therapeutic efficiency and focus on the beneficial effects of hydrogels in MSC-based therapy for AKI and CKD.
Impact statement
Hydrogels have been widely applied in the field of drug delivery and regenerative medicine, including mesenchymal stem cell (MSC)-based therapy. Many studies have proven that hydrogels can improve the therapeutic efficacy of MSCs for kidney diseases, but only a few articles summarized the application of hydrogels in MSC-based therapy for kidney diseases. In this review, we focus on the beneficial effects of hydrogels in MSC-based therapy for acute kidney injury and chronic kidney disease by introducing promising results in recent studies. We also discussed challenges in the clinical translation and widespread application of hydrogels in MSC-based therapy for kidney diseases.
Get full access to this article
View all access options for this article.
References
1.
OstermannM, BellomoR, BurdmannEA, et al.Controversies in acute kidney injury: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney Int, 2020; 98(2):294–309; doi: 10.1016/j.kint.2020.04.020
2.
Al-JaghbeerM, DealmeidaD, BilderbackA, et al.Clinical decision support for in-hospital AKI. J Am Soc Nephrol, 2018; 29(2):654–660; doi: 10.1681/ASN.2017070765
3.
BikbovB, PurcellCA, LeveyAS, et al.Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2020; 395(10225):709–733; doi: 10.1016/s0140-6736(20)30045-3
KaushalGP, ShahSV. Challenges and advances in the treatment of AKI. J Am Soc Nephrol, 2014; 25(5):877–883; doi: 10.1681/asn.2013070780
7.
BrownEA, JohanssonL. Epidemiology and management of end-stage renal disease in the elderly. Nat Rev Nephrol, 2011; 7(10):591–598; doi: 10.1038/nrneph.2011.113
8.
CatarR, MollG, Kamhieh-MilzJ, et al.Expanded hemodialysis therapy ameliorates uremia-induced systemic microinflammation and endothelial dysfunction by modulating VEGF, TNF-α and AP-1 signaling. Front Immunol, 2021; 12:774052; doi: 10.3389/fimmu.2021.774052
9.
CatarRA, BartosovaM, KawkaE, et al.Angiogenic role of mesothelium-derived chemokine CXCL1 during unfavorable peritoneal tissue remodeling in patients receiving peritoneal dialysis as renal replacement therapy. Front Immunol, 2022; 13:821681; doi: 10.3389/fimmu.2022.821681
10.
RoemhildA, OttoNM, MollG, et al.Regulatory T cells for minimising immune suppression in kidney transplantation: Phase I/IIa clinical trial. BMJ, 2020; 371:m3734; doi: 10.1136/bmj.m3734
11.
MushaharyD, SpittlerA, KasperC, et al.Isolation, cultivation, and characterization of human mesenchymal stem cells. Cytometry A, 2018; 93(1):19–31; doi: 10.1002/cyto.a.23242
12.
ViswanathanS, ShiY, GalipeauJ, et al.Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy, 2019; 21(10):1019–1024; doi: 10.1016/j.jcyt.2019.08.002
13.
BiancoP, CaoX, FrenettePS, et al.The meaning, the sense and the significance: Translating the science of mesenchymal stem cells into medicine. Nat Med, 2013; 19(1):35–42; doi: 10.1038/nm.3028
14.
FazekasB, GriffinMD. Mesenchymal stromal cell-based therapies for acute kidney injury: Progress in the last decade. Kidney Int, 2020; 97(6):1130–1140; doi: 10.1016/j.kint.2019.12.019
15.
WangJ, LinY, ChenX, et al.Mesenchymal stem cells: A new therapeutic tool for chronic kidney disease. Front Cell Dev Biol, 2022; 10:910592; doi: 10.3389/fcell.2022.910592
16.
YunCW, LeeSH. Potential and therapeutic efficacy of cell-based therapy using mesenchymal stem cells for acute/chronic kidney disease. Int J Mol Sci, 2019; 20(7):1619; doi: 10.3390/ijms20071619
ZhaoL, HuC, ZhangP, et al.Preconditioning strategies for improving the survival rate and paracrine ability of mesenchymal stem cells in acute kidney injury. J Cell Mol Med, 2019; 23(2):720–730; doi: 10.1111/jcmm.14035
19.
XuH, ChenC, HuL, et al.Gene-modified mesenchymal stem cell-based therapy in renal ischemia-reperfusion injury. Curr Gene Ther, 2017; 17(6):453–460; doi: 10.2174/1566523218666180214094253
20.
McFetridgeML, Del BorgoMP, AguilarMI, et al.The use of hydrogels for cell-based treatment of chronic kidney disease. Clin Sci (Lond), 2018; 132(17):1977–1994; doi: 10.1042/CS20180434
21.
KharkarPM, KiickKL, KloxinAM. Designing degradable hydrogels for orthogonal control of cell microenvironments. Chem Soc Rev, 2013; 42(17):7335–7372; doi: 10.1039/c3cs60040h
22.
GylesDA, CastroLD, SilvaJOC, et al.A review of the designs and prominent biomedical advances of natural and synthetic hydrogel formulations. Eur Polym J, 2017; 88:373–392; doi: https://doi.org/10.1016/j.eurpolymj.2017.01.027
23.
CorreaS, GrosskopfAK, Lopez HernandezH, et al.Translational applications of hydrogels. Chem Rev, 2021; 121(18):11385–11457; doi: 10.1021/acs.chemrev.0c01177
24.
YangJ, ZhangYS, YueK, et al.Cell-laden hydrogels for osteochondral and cartilage tissue engineering. Acta Biomater, 2017; 57:1–25; doi: 10.1016/j.actbio.2017.01.036
25.
MollG, AnkrumJA, Kamhieh-MilzJ, et al.Intravascular mesenchymal stromal/stem cell therapy product diversification: Time for new clinical guidelines. Trends Mol Med, 2019; 25(2):149–163; doi: 10.1016/j.molmed.2018.12.006
26.
CostaLA, EiroN, FraileM, et al.Functional heterogeneity of mesenchymal stem cells from natural niches to culture conditions: Implications for further clinical uses. Cell Mol Life Sci, 2021; 78(2):447–467; doi: 10.1007/s00018-020-03600-0
27.
UccelliA, MorettaL, PistoiaV. Mesenchymal stem cells in health and disease. Nat Rev Immunol, 2008; 8(9):726–736; doi: 10.1038/nri2395
28.
HanY, YangJ, FangJ, et al.The secretion profile of mesenchymal stem cells and potential applications in treating human diseases. Signal Transduct Target Ther, 2022; 7(1):92; doi: 10.1038/s41392-022-00932-0
29.
MishraVK, ShihHH, ParveenF, et al.Identifying the therapeutic significance of mesenchymal stem cells. Cells, 2020; 9(5):1145; doi: 10.3390/cells9051145
30.
MolinaER, SmithBT, ShahSR, et al.Immunomodulatory properties of stem cells and bioactive molecules for tissue engineering. J Controlled Release, 2015; 219:107–118; doi: 10.1016/j.jconrel.2015.08.038
31.
LanT, LuoM, WeiX. Mesenchymal stem/stromal cells in cancer therapy. J Hematol Oncol, 2021; 14(1):195; doi: 10.1186/s13045-021-01208-w
32.
BagnoL, HatzistergosKE, BalkanW, et al.Mesenchymal stem cell-based therapy for cardiovascular disease: Progress and challenges. Mol Ther, 2018; 26(7):1610–1623; doi: 10.1016/j.ymthe.2018.05.009
33.
MontanariS, DayanV, YannarelliG, et al.Mesenchymal stromal cells improve cardiac function and left ventricular remodeling in a heart transplantation model. J Heart Lung Transplant, 2015; 34(11):1481–1488; doi: 10.1016/j.healun.2015.05.008
34.
WangW, CaoW. Treatment of osteoarthritis with mesenchymal stem cells. Science China Life Sci, 2014; 57(6):586–595; doi: 10.1007/s11427-014-4673-7
35.
McGonagleD, BaboolalTG, JonesE. Native joint-resident mesenchymal stem cells for cartilage repair in osteoarthritis. Nat Rev Rheumatol, 2017; 13(12):719–730; doi: 10.1038/nrrheum.2017.182
36.
DelaRosaO, DalemansW, LombardoE. Mesenchymal stem cells as therapeutic agents of inflammatory and autoimmune diseases. Curr Opin Biotechnol, 2012; 23(6):978–983; doi: 10.1016/j.copbio.2012.05.005
37.
ShiY, WangY, LiQ, et al.Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol, 2018; 14(8):493–507; doi: 10.1038/s41581-018-0023-5
38.
AndrzejewskaA, DabrowskaS, LukomskaB, et al.Mesenchymal stem cells for neurological disorders. Adv Sci (Weinheim, Baden-Wurttemberg, Germany), 2021; 8(7):2002944; doi: 10.1002/advs.202002944
39.
HuJ, ZhangL, WangN, et al.Mesenchymal stem cells attenuate ischemic acute kidney injury by inducing regulatory T cells through splenocyte interactions. Kidney Int, 2013; 84(3):521–531; doi: 10.1038/ki.2013.114
40.
LiuD, ZhengW, PanS, et al.Concise review: Current trends on applications of stem cells in diabetic nephropathy. Cell Death Dis, 2020; 11(11):1000; doi: 10.1038/s41419-020-03206-1
41.
López-NovoaJM, Martínez-SalgadoC, Rodríguez-PeñaAB, et al.Common pathophysiological mechanisms of chronic kidney disease: Therapeutic perspectives. Pharmacol Ther, 2010; 128(1):61–81; doi: 10.1016/j.pharmthera.2010.05.006
42.
AgarwalA, DongZ, HarrisR, et al.Cellular and molecular mechanisms of AKI. J Am Soc Nephrol, 2016; 27(5):1288–1299; doi: 10.1681/asn.2015070740
43.
de AlmeidaDC, Donizetti-OliveiraC, Barbosa-CostaP, et al.In search of mechanisms associated with mesenchymal stem cell-based therapies for acute kidney injury. Clin Biochem Rev, 2013; 34(3):131–144.
44.
KuppeC, KramannR. Role of mesenchymal stem cells in kidney injury and fibrosis. Curr Opin Nephrol Hypertens, 2016; 25(4):372–377; doi: 10.1097/MNH.0000000000000230
45.
CorrêaRR, JuncosaEM, MasereeuwR, et al.Extracellular vesicles as a therapeutic tool for kidney disease: Current advances and perspectives. Int J Mol Sci, 2021; 22(11):5787; doi: 10.3390/ijms22115787
46.
MonteiroBS, SantosBSD, AlmeidaBL, et al.Adipose tissue derived mesenchymal stem cell transplantation in the treatment of ischemia/reperfusion induced acute kidney injury in rats. Application route and therapeutic window1. Acta Cir Bras, 2018; 33(11):1016–1026; doi: 10.1590/s0102-865020180110000008
47.
ZhuG, PeiL, LinF, et al.Exosomes from human-bone-marrow-derived mesenchymal stem cells protect against renal ischemia/reperfusion injury via transferring miR-199a-3p. J Cell Physiol, 2019; 234(12):23736–23749; doi: 10.1002/jcp.28941
48.
CaoH, ChengY, GaoH, et al.In vivo tracking of mesenchymal stem cell-derived extracellular vesicles improving mitochondrial function in renal ischemia-reperfusion injury. ACS Nano, 2020; 14(4):4014–4026; doi: 10.1021/acsnano.9b08207
49.
GuoJ, WangR, LiuD. Bone marrow-derived mesenchymal stem cells ameliorate sepsis-induced acute kidney injury by promoting mitophagy of renal tubular epithelial cells via the SIRT1/parkin axis. Front Endocrinol (Lausanne), 2021; 12:639165; doi: 10.3389/fendo.2021.639165
50.
LiuW, HuC, ZhangB, et al.Exosomal microRNA-342-5p secreted from adipose-derived mesenchymal stem cells mitigates acute kidney injury in sepsis mice by inhibiting TLR9. Biol Proc Online, 2023; 25(1):10; doi: 10.1186/s12575-023-00198-y
51.
GengY, ZhangL, FuB, et al.Mesenchymal stem cells ameliorate rhabdomyolysis-induced acute kidney injury via the activation of M2 macrophages. Stem Cell Res Ther, 2014; 5(3):80; doi: 10.1186/scrt469
52.
PengX, XuH, ZhouY, et al.Human umbilical cord mesenchymal stem cells attenuate cisplatin-induced acute and chronic renal injury. Exp Biol Med (Maywood), 2013; 238(8):960–970; doi: 10.1177/1477153513497176
53.
WangB, JiaH, ZhangB, et al.Pre-incubation with hucMSC-exosomes prevents cisplatin-induced nephrotoxicity by activating autophagy. Stem Cell Res Ther, 2017; 8(1):75; doi: 10.1186/s13287-016-0463-4
54.
ZojaC, GarciaPB, RotaC, et al.Mesenchymal stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy. Am J Physiol Renal Physiol, 2012; 303(9):F1370–F1381; doi: 10.1152/ajprenal.00057.2012
55.
LinS, LinW, LiaoC, et al.Nephroprotective effect of mesenchymal stem cell-based therapy of kidney disease induced by toxicants. Stem Cells Int, 2020; 2020:8819757; doi: 10.1155/2020/8819757
56.
YueY, YehJN, ChiangJY, et al.Intrarenal arterial administration of human umbilical cord-derived mesenchymal stem cells effectively preserved the residual renal function of diabetic kidney disease in rat. Stem Cell Res Ther, 2022; 13(1):186; doi: 10.1186/s13287-022-02857-5
57.
WuY, ZhangC, GuoR, et al.Mesenchymal stem cells: An overview of their potential in cell-based therapy for diabetic nephropathy. Stem Cells Int, 2021; 2021:6620811; doi: 10.1155/2021/6620811
58.
AnX, LiaoG, ChenY, et al.Intervention for early diabetic nephropathy by mesenchymal stem cells in a preclinical nonhuman primate model. Stem Cell Res Ther, 2019; 10(1):363; doi: 10.1186/s13287-019-1401-z
59.
EbrahimN, AhmedIA, HussienNI, et al.Mesenchymal stem cell-derived exosomes ameliorated diabetic nephropathy by autophagy induction through the mTOR signaling pathway. Cells, 2018; 7(12):226; doi: 10.3390/cells7120226
60.
HicksonLJ, AbedalqaderT, Ben-BernardG, et al.A systematic review and meta-analysis of cell-based interventions in experimental diabetic kidney disease. Stem Cells Transl Med, 2021; 10(9):1304–1319; doi: 10.1002/sctm.19-0419
61.
ZhouT, LiaoC, LiHY, et al.Efficacy of mesenchymal stem cells in animal models of lupus nephritis: A meta-analysis. Stem Cell Res Ther, 2020; 11(1):48; doi: 10.1186/s13287-019-1538-9
62.
ZhangL, ChenW, XiaN, et al.Mesenchymal stem cells inhibit MRP-8/14 expression and neutrophil migration via TSG-6 in the treatment of lupus nephritis. Biochem Biophys Res Commun, 2023; 650:87–95; doi: 10.1016/j.bbrc.2023.02.005
63.
WangD, LiJ, ZhangY, et al.Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: A multicenter clinical study. Arthrit Res Ther, 2014; 16(2):R79; doi: 10.1186/ar4520
64.
YeaJH, YoonYM, LeeJH, et al.Exosomes isolated from melatonin-stimulated mesenchymal stem cells improve kidney function by regulating inflammation and fibrosis in a chronic kidney disease mouse model. J Tissue Eng, 2021; 12:20417314211059624; doi: 10.1177/20417314211059624
65.
MatsuiF, BabitzSK, RheeA, et al.Mesenchymal stem cells protect against obstruction-induced renal fibrosis by decreasing STAT3 activation and STAT3-dependent MMP-9 production. Am J Physiol Renal Physiol, 2017; 312(1):F25–F32; doi: 10.1152/ajprenal.00311.2016
66.
VillanuevaS, EwertzE, CarrionF, et al.Mesenchymal stem cell injection ameliorates chronic renal failure in a rat model. Clin Sci (Lond), 2011; 121(11):489–499; doi: 10.1042/CS20110108
67.
PeiredAJ, SistiA, RomagnaniP. Mesenchymal stem cell-based therapy for kidney disease: A review of clinical evidence. Stem Cells Int, 2016; 2016:4798639; doi: 10.1155/2016/4798639
68.
MakhloughA, ShekarchianS, MoghadasaliR, et al.Safety and tolerability of autologous bone marrow mesenchymal stromal cells in ADPKD patients. Stem Cell Res Ther, 2017; 8(1):116; doi: 10.1186/s13287-017-0557-7
69.
MollG, AnkrumJA, OlsonSD, et al.Improved MSC minimal criteria to maximize patient safety: A call to embrace tissue factor and hemocompatibility assessment of MSC products. Stem Cells Transl Med, 2022; 11(1):2–13; doi: 10.1093/stcltm/szab005
70.
MollG, GeißlerS, CatarR, et al.Cryopreserved or fresh mesenchymal stromal cells: Only a matter of taste or key to unleash the full clinical potential of MSC therapy?. Adv Exp Med Biol, 2016; 951:77–98; doi: 10.1007/978-3-319-45457-3_7
71.
MollG, Rasmusson-DuprezI, von BahrL, et al.Are therapeutic human mesenchymal stromal cells compatible with human blood?. Stem Cells, 2012; 30(7):1565–1574; doi: 10.1002/stem.1111
72.
MollG, IgnatowiczL, CatarR, et al.Different procoagulant activity of therapeutic mesenchymal stromal cells derived from bone marrow and placental decidua. Stem Cells Dev, 2015; 24(19):2269–2279; doi: 10.1089/scd.2015.0120
TögelF, YangY, ZhangP, et al.Bioluminescence imaging to monitor the in vivo distribution of administered mesenchymal stem cells in acute kidney injury. Am J Physiol Renal Physiol, 2008; 295(1):F315–F321; doi: 10.1152/ajprenal.00098.2008
75.
SensebéL, Fleury-CappellessoS. Biodistribution of mesenchymal stem/stromal cells in a preclinical setting. Stem Cells Int, 2013; 2013:678063; doi :10.1155/2013/678063
76.
BurstVR, GillisM, PutschF, et al.Poor cell survival limits the beneficial impact of mesenchymal stem cell transplantation on acute kidney injury. Nephron Exp Nephrol, 2010; 114(3):e107–e116; doi: 10.1159/000262318
77.
El-BadawyA, El-BadriN. Clinical efficacy of stem cell therapy for diabetes mellitus: A meta-analysis. PLoS One, 2016; 11(4):e0151938; doi: 10.1371/journal.pone.0151938
78.
TaddeiML, GiannoniE, FiaschiT, et al.Anoikis: An emerging hallmark in health and diseases. J Pathol, 2012; 226(2):380–393; doi: 10.1002/path.3000
79.
DimarinoAM, CaplanAI, BonfieldTL. Mesenchymal stem cells in tissue repair. Front Immunol, 2013; 4:201; doi: 10.3389/fimmu.2013.00201
80.
LiY, LiuJ, LiaoG, et al.Early intervention with mesenchymal stem cells prevents nephropathy in diabetic rats by ameliorating the inflammatory microenvironment. Int J Mol Med, 2018; 41(5):2629–2639; doi: 10.3892/ijmm.2018.3501
81.
ZhaoL, HuC, HanF, et al.Preconditioning is an effective strategy for improving the efficiency of mesenchymal stem cells in kidney transplantation. Stem Cell Res Ther, 2020; 11(1):197; doi: 10.1186/s13287-020-01721-8
82.
ZhaoL, HuC, ZhangP, et al.Melatonin preconditioning is an effective strategy for mesenchymal stem cell-based therapy for kidney disease. J Cell Mol Med, 2020; 24(1):25–33; doi: 10.1111/jcmm.14769
83.
FengG, ZhangJ, LiY, et al.IGF-1 C domain-modified hydrogel enhances cell therapy for AKI. J Am Soc Nephrol, 2016; 27(8):2357–2369; doi: 10.1681/asn.2015050578
84.
UllahF, OthmanMB, JavedF, et al.Classification, processing and application of hydrogels: A review. Mater Sci Eng C Mater Biol Appl, 2015; 57:414–433; doi: 10.1016/j.msec.2015.07.053
85.
DalyAC, RileyL, SeguraT, et al.Hydrogel microparticles for biomedical applications. Nat Rev Mater, 2020; 5(1):20–43; doi: 10.1038/s41578-019-0148-6
86.
ZhangYS, KhademhosseiniA. Advances in engineering hydrogels. Science (New York, NY), 2017; 356:6337; doi: 10.1126/science.aaf3627
87.
CaoH, DuanL, ZhangY, et al.Current hydrogel advances in physicochemical and biological response-driven biomedical application diversity. Signal Transduct Target Ther, 2021; 6(1):426; doi: 10.1038/s41392-021-00830-x
88.
YaoY, YangL, FengLF, et al.IGF-1C domain-modified hydrogel enhanced the efficacy of stem cells in the treatment of AMI. Stem Cell Res Ther, 2020; 11(1):136; doi: 10.1186/s13287-020-01637-3
89.
PalmeseLL, ThapaRK, SullivanMO, et al.Hybrid hydrogels for biomedical applications. Curr Opin Chem Eng, 2019; 24:143–157; doi: 10.1016/j.coche.2019.02.010
90.
JonkerAM, LöwikDWPM, van HestJCM. Peptide- and protein-based hydrogels. Chem Mater, 2012; 24(5):759–773; doi: 10.1021/cm202640w
91.
DankersPY, van LuynMJ, Huizinga-van der VlagA, et al.Development and in-vivo characterization of supramolecular hydrogels for intrarenal drug delivery. Biomaterials, 2012; 33(20):5144–5155; doi: 10.1016/j.biomaterials.2012.03.052
92.
SlaughterBV, KhurshidSS, FisherOZ, et al.Hydrogels in regenerative medicine. Adv Mater (Deerfield Beach, Fla), 2009; 21(32–33):3307–3329; doi: 10.1002/adma.200802106
93.
KhayambashiP, IyerJ, PillaiS, et al.Hydrogel encapsulation of mesenchymal stem cells and their derived exosomes for tissue engineering. Int J Mol Sci, 2021; 22(2):684; doi: 10.3390/ijms22020684
94.
PiantanidaE, AlonciG, BertucciA, et al.Design of nanocomposite injectable hydrogels for minimally invasive surgery. Acc Chem Res, 2019; 52(8):2101–2112; doi: 10.1021/acs.accounts.9b00114
95.
HuangQ, ZouY, ArnoMC, et al.Hydrogel scaffolds for differentiation of adipose-derived stem cells. Chem Soc Rev, 2017; 46(20):6255–6275; doi: 10.1039/c6cs00052e
96.
GaoJ, LiuR, WuJ, et al.The use of chitosan based hydrogel for enhancing the therapeutic benefits of adipose-derived MSCs for acute kidney injury. Biomaterials, 2012; 33(14):3673–3681; doi: 10.1016/j.biomaterials.2012.01.061
97.
ZulloJA, NadelEP, RabadiMM, et al.The secretome of hydrogel-coembedded endothelial progenitor cells and mesenchymal stem cells instructs macrophage polarization in endotoxemia. Stem Cells Transl Med, 2015; 4(7):852–861; doi: 10.5966/sctm.2014-0111
98.
HuangS, LiY, WangX, et al.Injectable co-gels of collagen and decellularized vascular matrix improve MSC-based therapy for acute kidney injury. J Biomater Sci Polym Ed, 2017; 28(18):2186–2195; doi: 10.1080/09205063.2017.1388556
99.
WangH, ShangY, ChenX, et al.Delivery of MSCs with a hybrid β-sheet peptide hydrogel consisting IGF-1C domain and D-form peptide for acute kidney injury therapy. Int J Nanomed, 2020; 15:4311–4324; doi: 10.2147/ijn.S254635
100.
BuzásEI, TóthE, SódarBW, et al.Molecular interactions at the surface of extracellular vesicles. Semin Immunopathol, 2018; 40(5):453–464; doi: 10.1007/s00281-018-0682-0
101.
ZhangC, ShangY, ChenX, et al.Supramolecular nanofibers containing arginine-glycine-aspartate (RGD) peptides boost therapeutic efficacy of extracellular vesicles in kidney repair. ACS Nano, 2020; 14(9):12133–12147; doi: 10.1021/acsnano.0c05681
102.
NajafiH, AbolmaaliSS, HeidariR, et al.Integrin receptor-binding nanofibrous peptide hydrogel for combined mesenchymal stem cell therapy and nitric oxide delivery in renal ischemia/reperfusion injury. Stem Cell Res Ther, 2022; 13(1):344; doi: 10.1186/s13287-022-03045-1
103.
ChoSH, NohJR, ChoMY, et al.An injectable collagen/poly(γ-glutamic acid) hydrogel as a scaffold of stem cells and α-lipoic acid for enhanced protection against renal dysfunction. Biomater Sci, 2017; 5(2):285–294; doi: 10.1039/c6bm00711b
GelainF, LuoZ, RioultM, et al.Self-assembling peptide scaffolds in the clinic. NPJ Regen Med, 2021; 6(1):9; doi: 10.1038/s41536-020-00116-w
106.
ZhouY, LiuS, ZhaoM, et al.Injectable extracellular vesicle-released self-assembling peptide nanofiber hydrogel as an enhanced cell-free therapy for tissue regeneration. J Controlled Release, 2019; 316:93–104; doi: 10.1016/j.jconrel.2019.11.003
107.
DrzeniekNM, MazzocchiA, SchlickeiserS, et al.Bio-instructive hydrogel expands the paracrine potency of mesenchymal stem cells. Biofabrication, 2021; 13(4):045002; doi: 10.1088/1758-5090/ac0a32
108.
GengX, HongQ, ChiK, et al.Mesenchymal stem cells loaded with gelatin microcryogels attenuate renal fibrosis. Biomed Res Int, 2019; 2019:6749326; doi: 10.1155/2019/6749326
109.
AmirianJ, VanTTT, BaeSH, et al.Examination of In vitro and In vivo biocompatibility of alginate-hyaluronic acid microbeads As a promising method in cell delivery for kidney regeneration. Int J Biol Macromol, 2017; 105(Pt 1):143–153; doi: 10.1016/j.ijbiomac.2017.07.019
110.
FuZ, ChuY, GengX, et al.Artificial kidney capsule packed with mesenchymal stem cell-laden hydrogel for the treatment of rhabdomyolysis-induced acute kidney injury. ACS Biomater Sci Eng, 2022; 8(4):1726–1734; doi: 10.1021/acsbiomaterials.1c01595
111.
GhalyT, RabadiMM, WeberM, et al.Hydrogel-embedded endothelial progenitor cells evade LPS and mitigate endotoxemia. Am J Physiol Renal Physiol, 2011; 301(4):F802–F812; doi: 10.1152/ajprenal.00124.2011
112.
RatliffBB, GhalyT, BrudnickiP, et al.Endothelial progenitors encapsulated in bioartificial niches are insulated from systemic cytotoxicity and are angiogenesis competent. Am J Physiol Renal Physiol, 2010; 299(1):F178–F186; doi: 10.1152/ajprenal.00102.2010
113.
ZhouC, ZhouL, LiuJ, et al.Kidney extracellular matrix hydrogel enhances therapeutic potential of adipose-derived mesenchymal stem cells for renal ischemia reperfusion injury. Acta Biomater, 2020; 115:250–263; doi: 10.1016/j.actbio.2020.07.056
114.
LeeS, ChoiE, ChaMJ, et al.Cell adhesion and long-term survival of transplanted mesenchymal stem cells: A prerequisite for cell therapy. Oxid Med Cell Longev, 2015; 2015:632902; doi: 10.1155/2015/632902
115.
HeN, XuY, DuW, et al.Extracellular matrix can recover the downregulation of adhesion molecules after cell detachment and enhance endothelial cell engraftment. Sci Rep, 2015; 5:10902; doi: 10.1038/srep10902
116.
TsouYH, KhoneisserJ, HuangPC, et al.Hydrogel as a bioactive material to regulate stem cell fate. Bioact Mater, 2016; 1(1):39–55; doi: 10.1016/j.bioactmat.2016.05.001
117.
GengXD, ZhengW, WuCM, et al.Embryonic stem cells-loaded gelatin microcryogels slow progression of chronic kidney disease. Chin Med J, 2016; 129(4):392–398; doi: 10.4103/0366-6999.176088
